New MRI Agent Spots Lung Cancer Tumors as Small as One Millimeter

A Smarter Way to See What Scans Have Been Missing

Lung cancer with multiorgan metastasis remains the leading cause of cancer death, and current CT imaging and biopsy are suboptimal for detecting early tumors or subclinical metastases. That diagnostic gap — the window between when a cancer begins spreading and when doctors can actually see it — is where lives are lost. Now, a team of researchers believes they have found a way to close it.

A multi-institutional research team led by Georgia State University Regents' Professor Emerita of Biochemistry and Biophysical Chemistry Jenny J. Yang has developed a new class of protein-based MRI contrast agent that detects invasive lung cancer and metastatic disease at earlier stages than conventional imaging approaches. Results of this research, recently published in the journal Science Advances, report a precision MRI method that can identify tumors and metastases as small as 1 millimeter. To put that in perspective, that's roughly the size of a sesame seed — far smaller than what standard scans typically catch.

How the Agent Works

The research, partly funded by the National Institutes of Health, describes a protein-based MRI contrast agent, hProCA32.Collagen, which targets collagen type I, a structural protein found at elevated levels in aggressive lung tumors and metastatic lesions. This is a key distinction from conventional MRI contrast dyes, which flood the body indiscriminately. This agent goes looking for something specific — a molecular fingerprint that aggressive cancers leave behind.

hProCA32.Collagen exhibits 10-fold higher relaxivity than clinical contrast agents currently used, with strong gadolinium binding, high stability, and low toxicity risk. Precision MRI with hProCA32.Collagen enables early, noninvasive detection and quantification of lung tumors and metastases with improved contrast, outperforming CT and standard MRI — including simultaneous detection of primary tumors and metastases in the lung and adrenal glands, with collagen mapping.

What It Could Mean for Patients

"Lung cancer is often diagnosed only after it has spread, when treatment options become more limited," Yang said. "Our technology can detect tiny tumors and hidden metastases without exposing patients to radiation. It also helps reveal how aggressive a cancer may be and how likely it is to spread, potentially reducing the need for invasive biopsies." That last point is significant. Biopsies are uncomfortable, carry procedural risks, and can miss cancers that have spread to multiple organs.

In preclinical studies, this technology enabled researchers to detect and quantify small lung tumors and metastases in the lung, adrenal glands, and kidneys while mapping biological features linked to tumor invasion and progression. Similar to a previously reported imaging agent developed by Yang's team that targeted the cancer biomarker CXCR4, the hProCA32.collagen agent targets abnormal collagen development within the tumor microenvironment. The ability to simultaneously detect spread across multiple organs in a single scan is a capability current imaging simply doesn't offer reliably.

The Road Ahead

This biomarker-targeting approach represents a new generation of molecular imaging technology designed to enhance imaging and improve detection of cancerous cells at earlier stages of development. The research is still in preclinical stages, meaning human trials have not yet begun. But the science behind the agent is grounded in years of prior work — Yang's lab has a track record of translating protein-engineering innovations toward clinical use.

Earlier detection doesn't just improve survival odds — it opens the door to less aggressive treatment options. When a tumor is caught at one millimeter rather than several centimeters, the difference in a patient's treatment journey can be enormous. If hProCA32.Collagen clears the long road of clinical trials, it could fundamentally change how oncologists stage and treat one of the world's most lethal diseases — not by developing a new drug, but by finally being able to see what's already there.